Quarterly ResultAug 6, 2026, 07:09 AM
Immunocore Q2 Revenue $115.9M, YTD Net Income $12.2M
AI Summary
Immunocore Holdings plc reported strong financial results for Q2 2026, with revenue from therapy sales increasing to $115.9 million, up from $98.0 million in Q2 2025. For the six months ended June 30, 2026, the company achieved a net income of $12.2 million, a significant improvement from a net loss of $5.3 million in the prior year period. Basic net income per share for the six-month period was $0.24. The company also saw an increase in cash and cash equivalents to $484.9 million, reflecting continued commercial expansion of KIMMTRAK.
Key Highlights
- Q2 2026 revenue from therapy sales was $115.9 million, up from $98.0 million in Q2 2025.
- Six months 2026 net income was $12.2 million, compared to a net loss of $5.3 million in 2025.
- Six months 2026 basic EPS was $0.24, up from a loss of $0.11 in 2025.
- Cash and cash equivalents increased to $484.9 million as of June 30, 2026.
- Total assets grew to $1.12 billion as of June 30, 2026.
- US revenue for six months 2026 was $142.4 million.
- European revenue for six months 2026 was $68.5 million.
- KIMMTRAK is approved in 39 countries and launched in over 30.
Price Impact
More from IMCR